

the administration of anthelmintic drugs at the stage of intestinal invasion or in the acute phase is crucial for pregnancy and are not recommended in children less than 2 years old. Albendazole has a $\text{t}_{1/2} = 11$ h

therapy. In addition, because of the predominantly zoonotic importance of infection, the main efforts in many countries have focused on the control or elimination of *Trichinella* from the food chain [4]. Domestic pork and related products remain the most important source of *Trichinella* infection in humans, especially when pigs are raised under free-range or backyard production conditions.

The prevention and treatment of humans and animals are all important. In following text, we review new progress in the treatment and prevention of trichinellosis.

Treatments

Anthelmintics

Anthelmintics, primarily albendazole and mebendazole, are the principal drugs for the treatment of trichinellosis. Their mode of action is inhibition of microtubule polymerization by selectively binding to the β -tubulin monomer of the parasite, with little effect on binding the tubulin of the mammalian host [7]. The recommended dose of albendazole is 400 mg twice daily for 8 to 14 days; for mebendazole, it is 200 to 400 mg three times a day for 3 days, followed by 400 to 500 mg three times a day for 10 days. Both treatment schemes are suitable for adults and children; however, they are contraindicated during

e

(RCB2O) and HP⁻ -CD showed better activity than RCB2O alone

| | | | | | |
|--|---|------|------------|---|--|
| | Salmonella-delivered vaccine + rTs87 | Ts87 | DNA | Oral DNA vaccine + intramuscular boost with rTs87 | 46% ML reduction; |
| | DNA vaccine of pVAX1-TsMIF-TsMCD-1-mUb | | | intramuscular | 38% ML reduction |
| | Phage-displayed Ts87 peptides | | | Subcutaneous | 29% ML reduction |
| | Salmonella-expressed 30-mer of p43 antigen (ShdA) | | | Intranasal | 62% adult reduction |
| | Salmonella-expressed 30-mer of p43 antigen (MisL) | | Intranasal | Salmonella-30mer + boost with intraperitoneal 30mer | Adult and ML reduction |
| Recombinant proteins and epitopes-peptides vaccine | rTs-APase | | | Subcutaneous | 59% ML reduction; 38% adult reduction |
| | rTspSP-1.3 | | | Subcutaneous | 39% ML reduction |
| | Phage-displayed rTsp10 | | | Subcutaneous | 79% ML reduction; 63% adult reduction |
| | Salmonella-delivered Ts-cystatin | | Oral | | Accelerated worm expulsion; worm fecundity decline |
| | Salmonella-surface-anchored and secreted | | | | |

